sector: Notable Exits


Revance Therapeutics is developing the next generation of innovative products in dermatology and aesthetic medicine. Listed on NASDAQ in 2014.


Quantcast specializes in real-time advertising and audience measurement, allowing marketers and publishers to make the smartest choices as they buy and sell the most effective targeted advertising on the market.


Paradigm Therapeutics has developed a promising pipeline of novel drug discovery targets and compounds for pain, CNS disorders, prostate and breast cancer, diabetes, hyperlipidemia, and obesity. Acquired by Takeda Pharmaceutical in 2007


OptiMedica designs, develops, and commercialises technologies to treat major eye diseases and disorders. Acquired by Abbott Medical Optics in 2013.


Ooyala applies big data analytics to help its customers deliver better, more personalized viewing experiences on any screen, build bigger audiences and monetize IP-delivered video. Acquired by Telstra in 2014.


nuTonomy develops state-of-the-art software for autonomous vehicles (AVs). Spun out of Massachusetts Institute of Technology (MIT), the company is piloting a R&D fleet of self-driving AVs in Singapore which will pave the way for its rollout of the world’s smartest autonomous taxi fleet that could be hailed by a phone call or via a taxi …

nuTonomy Read More »


NeuroVision trains the brain to see sharper by performing a series of NeuroVision patented, computerised and customised visual tasks.


Moka is an integrated point-of-sale and payment platform for businesses of all sizes.


Moderna pioneers the discovery and development of messenger RNA (mRNA) therapeutics and vaccines, an entirely new class of medicines that directs the body’s cells to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals. Listed on NASDAQ in 2018.


MerLionPharma is progressing finafloxacin, a novel antibacterial candidate, for the treatment of urinary tract infections and the eradication of Helicobacter pylori in critical care and hospital indications.